What are the recommended drug therapies for ulcerative colitis?

Recommended Drug Therapies for Ulcerative Colitis

For moderate-to-severe ulcerative colitis, use infliximab, vedolizumab, upadacitinib, ozanimod, etrasimod, risankizumab, or guselkumab as first-line advanced therapies, with JAK inhibitors (upadacitinib, tofacitinib) and S1P modulators (ozanimod, etrasimod) demonstrating the highest efficacy for achieving and maintaining clinical remission. 1, 2

Treatment Algorithm by Disease Severity

Mild-to-Moderate Disease (Proctitis)

• Start with topical 5-ASA therapy as first-line treatment 3
• If inadequate response or intolerance: add oral 5-ASA or switch to topical corticosteroids
• Refractory proctitis requires escalation to oral corticosteroids, topical tacrolimus, JAK inhibitors, S1P agonists, or biologic therapy 3

Mild-to-Moderate Disease (Beyond Rectum)

• Initiate oral 5-ASA, which can be combined with topical 5-ASA 3
• If no response within 2-4 weeks: start oral corticosteroids (prednisolone)
• High-dose 5-ASA alone can be considered, but switch to corticosteroids if no response within 2 weeks 3

Moderate-to-Severe Disease

First-Line Advanced Therapy Selection (Treatment-Naïve Patients):

The 2024 AGA guidelines stratify medications by efficacy tier 1:

HIGHER Efficacy Medications (Preferred):

• Infliximab (anti-TNF)
• Vedolizumab (anti-integrin)
• Upadacitinib (JAK inhibitor)
• Ozanimod (S1P modulator)
• Etrasimod (S1P modulator)
• Risankizumab (anti-IL-23)
• Guselkumab (anti-IL-23)

INTERMEDIATE Efficacy Medications:

• Golimumab (anti-TNF)
• Ustekinumab (anti-IL-12/23)
• Tofacitinib (JAK inhibitor)
• Filgotinib (JAK inhibitor)
• Mirikizumab (anti-IL-23)

LOWER Efficacy Medications (Avoid as First-Line):

• Adalimumab (anti-TNF)

Evidence-Based Efficacy Rankings

The most recent 2026 network meta-analysis provides definitive efficacy rankings 2:

For Induction of Clinical Remission:

1. JAK-STAT inhibitors (SUCRA 91.5%, RR=4.5 vs placebo)
2. Anti-TL1A biologics (SUCRA 82.3%, RR=4.0 vs placebo)
3. Anti-TNF-α biologics (SUCRA 70.1%, RR=3.0 vs placebo)

For Maintenance of Clinical Remission:

1. JAK-STAT inhibitors (SUCRA 86.3%)
2. S1P receptor modulators (SUCRA 80.5%)
3. Anti-IL-23 biologics (SUCRA 59.4%)

Critical Implementation Considerations

JAK Inhibitor Restrictions

FDA labeling restricts JAK inhibitors to patients who have failed or are intolerant to TNF antagonists 1. However, European Medicines Agency recommends cautious first-line use, particularly avoiding in patients with:

• Age ≥65 years
• Current or previous long-term smokers
• History of cardiovascular disease
• History of cancer

Safety Profile Considerations

Vedolizumab demonstrates superior safety with 32% lower risk of serious infections compared to TNF antagonists in UC patients 1. This makes it an excellent choice for:

• Elderly patients
• Those with infection risk factors
• Patients requiring long-term immunosuppression

JAK inhibitors carry increased infection risk in older adults with cardiovascular risk factors, based on the ORAL surveillance trial in rheumatoid arthritis 1. Balance this against their superior efficacy.

Practical Dosing Strategies

• Biosimilars of infliximab, adalimumab, and ustekinumab are equivalent to originators 1
• Subcutaneous formulations of infliximab and vedolizumab show comparable efficacy to IV maintenance 1
• Extended induction regimens (up to 16 weeks) or dose escalation may benefit patients with severe disease 1

Common Pitfalls to Avoid

1. Do not use corticosteroids for maintenance therapy - only for induction 3
2. Do not continue 5-ASA monotherapy or immunomodulators alone in moderate-to-severe disease - they show no significant benefit over placebo 2
3. Do not delay advanced therapy if inadequate response to oral corticosteroids within 2 weeks, unsuccessful steroid taper, or to avoid repeated corticosteroid courses 3
4. Do not underdose or persist with failing therapy - this increases complication risk and reduces quality of life

Treatment Goals

Shift from clinical response to achieving complete remission assessed biochemically, endoscopically, and histologically 3. Active disease and ongoing corticosteroid use are major determinants of adverse safety outcomes; achieving steroid-free remission reduces overall infection likelihood 1.